ClinicalTrials.gov record NCT02798705
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis
Physiologic Assessment of Microvascular Function in Patients With Cardiac Amyloidosis: Prospective Registry and Pilot Study
AI summaryWhat this study is about, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
This is a prospective observational study of people with cardiac amyloidosis that measures coronary microvascular function. It collects invasive physiologic measurements (CFR, IMR, fractional flow reserve) and compares them with non‑invasive imaging and blood tests, and with biopsy-measured amyloid involvement. The study aims to enroll at least 30 patients and follows outcomes for 2 years, including all-cause mortality.
What it is studying. The study is testing whether people with cardiac amyloidosis have measurable coronary microvascular dysfunction by assessing CFR and IMR and estimating how many meet a predefined definition of overt microvascular disease (depressed CFR plus elevated IMR). It also looks at how these physiologic measurements relate to non‑invasive tests (echocardiography, perfusion MRI), blood markers (serum light chains, NT‑proBNP, troponin T), pathologic amyloid burden, and clinical outcomes.
What the researchers hope to learn. Scientifically, the study aims to quantify coronary microvascular dysfunction in cardiac amyloidosis, compare invasive physiologic indices with non‑invasive imaging and blood markers, examine associations with biopsy-measured myocardial amyloid burden, and identify physiologic cut-offs related to all‑cause mortality.
What this study is about
The study's own summary, as published on ClinicalTrials.gov. Underlined terms have a short explanation.
The aim of the study is to evaluate coronary flow reserve (CFR), index of microcirculatory resistance (IMR), and proportion of overt microvascular disease, defined as depressed CFR as well as elevated IMR in patients with cardiac amyloidosis. The second objective of this study is to compare results of non-invasive test including serum light chain amount, Doppler echocardiography with 2D strain, and cardiac perfusion MRI. The third object of this study is to evaluate the association between physiologic indices and pathologically measured percent area involvement of interstitium.
Eligibility
The criteria exactly as listed on ClinicalTrials.gov. Only the study team can say whether they apply to you.
Inclusion criteria
- Subject age 18-85 years old
- Patients with confirmed cardiac amyloidosis by heart biopsy
- Patients with confirmed amyloidosis by biopsy other than heart and evidence of cardiac involvement in echocardiography
- Patients who underwent invasive physiologic assessment within 3 months from diagnosis of primary disease
Exclusion criteria
- Patients with cardiogenic shock
- Patients with unstable vital sign that precludes coronary angiography
- Patients with major bleeding in last 3 months
- Patients with active bleeding
- Patients with coagulopathy
- Patients with severe valvular heart disease
- Patients who refused to provide informed consent
Study description and what participation involves
The study's detailed description, as published on ClinicalTrials.gov.
Show the detailed description from the registry
Amyloidosis is rare systemic disorder characterized by the extracellular deposition of misfolded protein in various organ system, including heart. Among the several types of amyloid fibrils, the light chain and transthyretin amyloid proteins most commonly affect the heart. Cardiac amyloid deposits result in increased ventricular wall thickness and produce a restrictive cardiomyopathy presenting primarily as biventricular congestive heart failure. Anginal symptoms and signs of ischemia have been reported in some patients with cardiac amyloidosis without obstructive epicardial coronary artery disease (CAD). Autopsy studies have shown amyloid deposits around and between cardiac myocytes in the interstitium, the perivascular regions, and the media of intramyocardial coronary vessels. Amyloidosis is thus a prime example of a disorder with the potential to cause coronary microvascular dysfunction via 3 major mechanisms: (1) structural (amyloid deposition in the vessel wall causing wall thickening and luminal stenosis), (2) extravascular (extrinsic compression of the microvasculature from perivascular and interstitial amyloid deposits and decreased diastolic perfusion), and (3) functional (autonomic and endothelial dysfunction). Previous basic research presented that adipose arteriole or atrial coronary arterioles showed endothelial dysfunction even after brief exposure to physiologic amounts of light chain, and also showed increased oxidative stress, reduced NO bioavailability, and peroxynitrite production. All these previous evidences imply that coronary microvascular dysfunction and subsequent global ischemic insult can be precursor of overt diastolic or systolic dysfunction in patients with cardiac amyloidosis. However, there have only 1 study which evaluated microvascular function in vivo using N13-ammonium positron emission tomography (PET). In that study, Dorbala et al. demonstrated that amyloidosis patients showed depressed global resting myocardial blood flow (MBF), stress MBF, and CFR and higher minimal coronary vascular resistance, compared with patients with left ventricular hypertrophy. However, low availability, high cost, and limited resolution of N13 ammonium PET precludes the generalizability of the results. Since thermodilution-derived coronary flow reserve and index or microcirculatory reserve using pressure-temperature wire has been well validated prognostic index in assessment of patients with coronary artery disease or functionally insignificant epicardial coronary stenosis, invasive physiologic assessment might more specifically assess macro- and microvascular function in patients with cardiac amyloidosis. Moreover, adding physiologic measurement in the current frame in diagnosis of cardiac amyloidosis might enhance risk stratification of patients. Therefore, the current study will perform physiologic assessment including fractional flow reserve, coronary flow reserve, and index of microcirculatory resistance in patients with cardiac amyloidosis, and explore correlation among the physiologic indices and conventional measurements of echocardiography, perfusion MRI, serum light chain amount, or NT-proBNP. In addition, the differences of physiologic indices according to disease severity of cardiac amyloidosis, which measured by endomyocardial biopsy findings will be also explored. Since there was no previous study which performed invasive physiologic assessment in amyloidosis patients, this study will be performed as pilot study. Target sample size will be at least 30 patients.
AI summaryWhat participation may involve, in plain languageShow ▾Hide ▴
AI-written from the registry record, not the study's own wording. May contain errors or omissions. Check the registry text on this page and the original record ↗ before acting on it.
The study involves invasive physiologic measurements of coronary function — fractional flow reserve (FFR), coronary flow reserve (CFR), and index of microcirculatory resistance (IMR) — performed in association with coronary angiography as described in the record. It also compares those invasive results with non‑invasive tests such as blood tests (serum free light chain, troponin T, NT‑proBNP), Doppler echocardiography with 2D strain, and cardiac perfusion imaging (for example, perfusion MRI or adenosine‑SPECT). Participants are followed for outcomes including all‑cause mortality over a two‑year period, and many comparisons are planned within about three months of diagnosis. The registry requires pathologic confirmation of amyloidosis by biopsy (heart biopsy or another biopsy with echocardiographic evidence of cardiac involvement) and states participants must have undergone invasive physiologic assessment within three months of diagnosis; the record does not clearly say whether those procedures must have been done before enrollment or are performed by the study.
How the study is structured. A prospective observational cohort: participants have invasive physiologic measurements (fractional flow reserve, CFR, IMR) and undergo non‑invasive tests and blood marker assessments as described in the record. The study analyzes relationships among physiologic indices, imaging, blood tests, and pathology, and tracks outcomes over a 2‑year period. Target enrollment is at least 30 patients.
Questions you could ask
These questions are suggestions for a conversation with the study team or your own clinician, not advice.
- The registry lists this study under Cardiac Amyloidosis. Does it apply to my diagnosis?
- This is an observational study, so the study itself gives no treatment. What would taking part involve for me, and would it change my usual care?
- The listed sites are in South Korea. Is any of them reachable for me, and does the study help with travel?
- Which of the eligibility criteria would need to be checked with tests before I could join?
More on ATTRv amyloidosis
This trial is also listed on this site under wild-type ATTR amyloidosis.
Important dates
- Study start
- Apr 11, 2016
- Primary completion
- April 2029 (estimated)
- Study completion
- December 2030 (estimated)
- Target enrollment
- 30 participants (estimated)
- Last updated on registry
- Mar 14, 2025
- Data verified
- Oct 10, 2026
Sponsor and research team
The lead sponsor funds and oversees the trial. A pharmaceutical or biotech company sponsor typically means the study is testing that company's drug or device; a hospital, university, or government agency usually indicates investigator-initiated or publicly funded research.
- Lead sponsor
- Samsung Medical Center
- Principal investigator
- Joo Myung Lee, Assistant professor
Samsung Medical Center
Central study contact
If you're interested in participating, the central contact can answer general questions about the study — including eligibility requirements and how to find a recruiting site near you. Actual eligibility is determined by the site's medical team.
- Joo Myung Lee, MD, MPH, PhD 📞 82-2-3410-1246 ✉ drone80@hanmail.net
- Ki Hong Choi, MD 📞 82-2-3410-1246 ✉ cardiokh@gmail.com
Participating sites (1)
- Samsung Medical CenterRecruiting
Seoul · South Korea
- Joo Myung Lee, MD, MPH · 82-2-3410-1246 · drone80@hanmail.net
Terms used on this page · explanations by MedicalUpdates.ai
- echocardiography
- An ultrasound scan of the heart. A transesophageal echocardiogram is done through a probe passed into the food pipe for a closer view.
- MRI
- A scan that uses magnets and radio waves, not X-rays, to make detailed pictures of the inside of the body. Some implants and metal objects mean a person cannot have one.
- biopsy
- Removal of a small piece of tissue so it can be examined under a microscope. 'Biopsy-proven' or 'histologically confirmed' means the diagnosis was confirmed by examining tissue under a microscope.
- informed consent
- The process of explaining a study, including its risks and what participation involves, so that a person can decide freely whether to take part. Consent is usually documented in writing, and a participant can choose to leave the study later.
- Inclusion Criteria
- The conditions a person must meet to be considered for the study, for example a confirmed diagnosis, an age range or a test result.
- Exclusion Criteria
- The conditions that rule a person out even if they meet the inclusion criteria, for example other illnesses, certain medicines or pregnancy.
- positron emission tomography
- A scan in which a small amount of a radioactive tracer is injected so that activity in tissues can be seen. Often combined with a CT or MRI scan.
The study record on this page is reproduced from ClinicalTrials.gov, a database of the U.S. National Library of Medicine, where it was submitted by the study sponsor. MedicalUpdates.ai does not own this content, is not affiliated with or endorsed by ClinicalTrials.gov, NIH, or the U.S. Government, and does not verify the record. Plain-language notes, the glossary and the questions above are added by this site; text in the boxes marked "AI summary" was written by an AI model and may contain errors. Registry records change over time. Check the original record for the current version and discuss eligibility or participation with a qualified healthcare professional.
← Back to clinical trials